Webinar · Palm Beach, Florida
Regulatory Affairs in Biosimilars EU vs US
Medicine · Pharmaceuticals · Biotechnology
Key numbers
- Editions on record
- 1first in 2014
About Regulatory Affairs in Biosimilars EU vs US
By the end of this decade, a significant number of blockbuster drugs will go off patent, allowing a large number of biosimilar products to enter the market.
- Learn about the latest global regulatory challenges and developments in biosimilar pharmaceutical products
- Analyze current regulatory requirements for biosimilars approval in Europe and USA and the future path of this legislation
- Review the variations between EU and US law and regulations and learn about the process for gaining scientific advice from the FDA and EMA
- Discuss what are the key differences between comparability and biosimilarity from a regulatory perspective
Exclusive Speaker Panel
Speaker Benita von Glahn
Liz Fuller
Cecil Nick
Sharon Longhurst, PhD
Catherine Akers
From our listing of this edition. Details may have changed since.
Editions
| Year | Dates | Where | Exhibitors | Visitors |
|---|---|---|---|---|
| 2014 | 9 Jul 2014 | Webinar Venue Online | — | — |
Past editions from the bvents archive (2008–2019) and organiser figures where they were published.
Questions
When is Regulatory Affairs in Biosimilars EU vs US?
The next dates haven't been confirmed. The last edition we have on record was 9 Jul 2014.
Where is it held?
The last edition we have was at Webinar Venue, Palm Beach, Florida.